Memory and as well as connections between brain cells were restored in mice with a model of Alzheimer's given an experimental cancer drug.
Teva announces the launch of the generic equivalent to Exforge (amlodipine and valsartan)...
Teva Pharmaceutical Industries Ltd. is buying Auspex Pharmaceuticals Inc. for about $3.2 billion...
Genentech, a member of the Roche Group, has announced plans to invest more than $125 million for...
The goal of the collaboration is to discover and develop novel therapies to treat rare diseases with high unmet medical need combining Shire's development and commercialization capabilities with Cincinnati Children's research expertise.
AstraZeneca today announced that it has joined a public-private consortium with Genomics England to accelerate the development of new diagnostics and treatments arising from the 100,000 Genomes Project.
AstraZeneca has entered into a five-year research collaboration with the Harvard Stem Cell Institute (HSCI) to adapt a technique that creates human beta cells from stem cells for use in screens of AstraZeneca’s compound library in the search for new treatments for diabetes.
Merck & Co. says its board approved the repurchase of up to $10 billion more of its stock. The company said that amount will be added to the $1.7B remaining available for repurchase under a prior authorization.
Lycera Corp. today announced the achievement of a milestone under the Company's collaboration agreement with Merck, known as MSD outside the United States and Canada, triggering an undisclosed payment.
Gilead Sciences Canada today announced that multiple provinces will provide public access to Harvoni ™ (ledipasvir/sofosbuvir), the first once-daily, single tablet regimen for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection in adults.
BMS Acquires Exclusive License from Novo Nordisk for a Discovery Research Program Focused on Autoimmune DiseasesMarch 24, 2015 8:16 am | News | Comments
Bristol-Myers Squibb Company has signed an agreement with Novo Nordisk under which Bristol-Myers Squibb will acquire an exclusive global license to a discovery biologics research program focused on modulating the innate immune system as a therapy for autoimmune diseases.
Takeda will use ImmunoGen's technology to develop cancer treatments. ImmunoGen will get $20 million upfront and is eligible for milestone payments potentially totaling up to $210 million, plus royalties on sales.
Teva Pharmaceutical Industries has announced the appointment of Timothy R. Wright to the Company’s executive leadership team, heading business development, strategy and innovation.
Biogen released much anticipated results from a study of a potential Alzheimer's disease treatment on Friday, showing that it slowed cognitive decline in some patients.
Effective today, Biogen Idec is known simply as Biogen. The company has introduced a new corporate identity and logo that reflect both its evolution and focus on bringing forth new therapies in areas of high unmet needs.
Pfizer and Eli Lilly announced today that they are preparing to resume the Phase 3 clinical program for tanezumab. As a result, Pfizer expects to receive a $200 million upfront payment from Lilly in accordance with their collaboration agreement.
Government health advisers say a once-a-day respiratory inhaler from GlaxoSmithKline appears safe and effective for adults with asthma, but not for adolescents.
Biogen Idec released much anticipated results from a study of a potential Alzheimer's disease treatment on Friday, showing that it slowed cognitive decline in some patients.
A huge study of Pfizer's blockbuster vaccine against pneumonia and other bacterial infections in adults 65 and older found it protected most of them against dangerous infections in the bloodstream and other sterile body areas.
Under the terms of the agreement, Daiichi Sankyo will pay a $200M up-front fee and subsequent sales-related payments of up to $625M. AstraZeneca will be responsible for manufacturing, will book all sales and will make sales-related commission payments to Daiichi Sankyo.
Janssen has announced that a pre-planned interim analysis of the Phase 3 HELIOS study investigating the combination of IMBRUVICA plus bendamustine and rituximab (BR) versus placebo plus BR in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, showed the trial has met its primary endpoint.
Galapagos NV has announced that Janssen Pharmaceutica NV and Galapagos have mutually agreed to terminate the inflammation alliance and option agreements between the companies.
Indiana's Medicaid program will receive more than $126,000 from a drug manufacturer that filed false claims to Medicaid and other federally funded health care programs.
Valeant is raising its offer for Salix Pharmaceuticals to about $11.11 billion, heating up a bidding fight for the company.
The company said Friday that the Food and Drug Administration has canceled a March 18 meeting to review sugammadex, which is designed to help patients "wake up" after surgical anesthesia.
New research boosts hope that a highly anticipated, experimental class of cholesterol drugs can greatly lower the risk for heart attacks, death and other heart-related problems. The government will decide this summer whether to allow two of these drugs on the market.
The National Advertising Division--an industry regulatory agency administered by the Council of Better Business Bureaus--investigated Prestige Brands Holdings' Little Remedies products following a complaint by Pfizer.
GlaxoSmithKline has announced the completion of the disposal of half of its 12.4% shareholding in Aspen. Following settlement of the sale, GSK will hold 28.2 million ordinary shares in Aspen, representing approximately 6.2% of the issued share capital.
Pfizer has announced top-line results of a double-blind Phase 4 study evaluating the safety and efficacy of Lyrica® (pregabalin) Capsules CV in adolescents (ages 12-17 years) with fibromyalgia (FM).
- Page 1